Expert Says Melanoma Clinical Trials Should Include More Patients With Brain Mets

Source: OncLive, December 2017

Historically, patients with melanoma who develop brain metastases have been excluded from clinical trials, according to Harriet Kluger, MD.
As of late, an increasing number of patients in this subgroup are being included now on studies, particularly those who have received prior treatment. Yet this is still not enough, says Kluger, as brain metastases is no longer the dismal prognosis that it once was.
Kluger highlighted the systemic treatment of patients with melanoma with brain metastases in her talk at the 2017 OncLive® State of the Science SummitTM on Melanoma. In an interview during the meeting, Kluger, professor of medicine, associate cancer center director for Education and Training, Yale Cancer Center, discussed the lack of clinical trial inclusion as well as promising regimens coming down the pike.